Forum · Medicine · Story discussion
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
Remibrutinib was superior to teriflunomide in patients with relapsing multiple sclerosis, while maintaining a favourable safety profile. These findings support remibrutinib as a potential new oral treatment option for…
28 days ago — The Lancet · Read the original
Peer reviews (0)
Comments (0)
No comments yet. Start the discussion.
Loading sign-in…